Analyst upgrades, especially from reputable firms like Goldman Sachs, can significantly influence investor sentiment and stock prices. The upgrade from Neutral to Buy suggests a strong confidence in CG Oncology's future performance, potentially leading to increased investor interest and a rise in stock price in the short term.